TYO:130A

Veritas In Silico and Takeda Mutually Terminate mRNA-Targeted Drug Research Collaboration

Veritas In Silico (TYO:130A) and Takeda Pharmaceutical (TYO:4502) have mutually agreed to terminate their collaborative drug discovery research on mRNA-targeted small-molecule drugs, effective immediately.Although the research has produced some results since the agreement began in June 2023, the parties will now discuss and consider potential future applications of the findings gained from the collaboration, according to a Tokyo bourse filing on the same day.Veritas In Silico expects the termination's impact on its business performance to be limited, with no change to its earnings forecast for the fiscal year ending December, and will promptly disclose any material developments if they arise.